News
Latest News
Stay updated with GRP Japan
News by Topic
Filter the latest news by choosing categories below.
Global Regulatory Partners Announces MHLW Approval of Pegfilgrastim Biosimilar in Japan
Tokyo, Japan – August 25, 2026 – Global Regulatory Partners GK (GRP GK) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) granted marketing approval on August 24, 2026, for Pegfilgrastim BS Subcutaneous Injection 3.6 mg 「GRP」, a pegfilgrastim biosimilar indicated for the prevention of febrile neutropenia associated with cancer chemotherapy.
